<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03517865</url>
  </required_header>
  <id_info>
    <org_study_id>iPCD cohort</org_study_id>
    <nct_id>NCT03517865</nct_id>
  </id_info>
  <brief_title>International Primary Ciliary Dyskinesia Cohort</brief_title>
  <acronym>iPCD</acronym>
  <official_title>International Primary Ciliary Dyskinesia Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southampton</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pierre and Marie Curie University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bar-Ilan University, Israel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Gasthuisberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Marmara University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruhr University of Bochum</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genetic Disorders of Mucociliary Clearance Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Tuberculosis and Lung Disorders, Rabka Poland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sydney</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copenhagen University Hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Ni√±os R. Gutierrez de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cyprus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Centre Dr Dragisa Misovic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hacettepe University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Motol</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinica de neumologia pediatrica Compensar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Attikon Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Leicester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Bern</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The iPCD Cohort is a retrospective international cohort that assembles available datasets
      with clinical and diagnostic data from patients suffering from primary ciliary dyskinesia
      (PCD) worldwide, to answer pertinent questions on clinical phenotype, disease severity,
      prognosis and effect of treatments in patients with this rare multiorgan disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The iPCD Cohort was set up under the framework of the European Union (EU) funded 7th
      Framework Programme (FP7) project Better Experimental Screening and Treatment for Primary
      Ciliary Dyskinesia (BESTCILIA). The iPCD Cohort is hosted at the Institute of Social and
      Preventive Medicine at the University of Bern, Switzerland. Research is performed in close
      collaboration with all data contributors.

      Aims:

      This combined international dataset allows investigation of PCD epidemiology in a large
      international study population in order to: 1) describe the spectrum of clinical phenotypes
      and disease severity in PCD patients by age, sex and time period of diagnosis; 2) describe
      short-term and long-term prognosis of PCD, looking at important outcomes such as growth, lung
      function and respiratory failure, bacterial colonisation, hearing loss, fertility, and
      mortality; and 3) identify predictors of long-term outcomes such as age at diagnosis,
      clinical phenotype, ultrastructural defects, genotype and clinical care.

      Study design:

      The iPCD Cohort is a retrospective international cohort, combining available data on PCD from
      national or local registries and clinical or diagnostic databases. All participating centres
      delivered retrospectively collected data; new centres joining the iPCD Cohort in the future
      can also participate with retrospectively collected data.

      What information is collected:

      The iPCD Cohort includes retrospectively collected patient data on the following 11 thematic
      categories: 1) general information, 2) results of diagnostic tests, 3) baseline
      characteristics, 4) growth and lung function, 5) clinical manifestations, 6) therapy, 7)
      microbiology, 8) imaging, 9) surgical interventions, 10) neonatal period, and 11) family
      history.

      Study database:

      The iPCD Cohort database is web-based, using the Research Electronic Data Capture (REDCap)
      platform developed at Vanderbilt University. REDCap is widely used in academic research and
      allows data entry and extraction in various formats.

      How to participate:

      Centres that wish to participate to the project and contribute data can contact the iPCD
      Cohort to sign a data delivery agreement. They then will receive a password to access the
      online software REDCap and they will be able to enter their data directly. They can also
      upload follow-up data or add additional patients at a later time point.

      For further details, contact: pcd@ispm.unibe.ch

      Funding:

      The setting up of the iPCD Cohort (salaries, consumables and equipment) was funded by the EU
      FP7 project BESTCILIA (http://bestcilia.eu) and several Swiss funding bodies, including the
      Lung Leagues of Bern, St Gallen, Vaud, Ticino and Valais and the Milena Carvajal
      Pro-Kartagener Foundation. Data collection and management at each site was funded according
      to local arrangements. Most participating researchers and data contributors participate in
      the European Cooperation in Science and Technology (COST) Action &quot;Better Evidence to Advance
      Therapeutic options for PCD&quot; (BEAT-PCD) (BM 1407; www.beatpcd.org). Infrastructure is
      provided for free by the University of Bern, where the data are pooled and stored.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Anticipated">December 2030</completion_date>
  <primary_completion_date type="Anticipated">December 2028</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Height</measure>
    <time_frame>every 3 months up to 10 years</time_frame>
    <description>Height z-scores calculated based on available national and international references</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BMI</measure>
    <time_frame>every 3 months up to 10 years</time_frame>
    <description>Body Mass Index (BMI) z-scores calculated based on available national and international references</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lung function measurements</measure>
    <time_frame>every 3 months up to 10 years</time_frame>
    <description>Spirometric indices, particularly Forced expiratory volume in 1 sec (FEV1) and Forced vital capacity (FVC) z-scores calculated based on Global Lung Function Initiative (GLI) reference values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic test results</measure>
    <time_frame>at diagnosis/ study entry</time_frame>
    <description>Results of performed PCD diagnostic tests including measurement of nasal nitric oxide, electron microscopy findings, beat frequency and pattern.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical symptoms and signs</measure>
    <time_frame>every 3 months up to 10 years</time_frame>
    <description>Prevalence of reported clinical symptoms at different age groups, including rhinitis, cough, otitis, sinusitis, pneumonia, laterality defects, congenital heart disease and fertility problems.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microbiology results</measure>
    <time_frame>every 3 months up to 10 years</time_frame>
    <description>Results of microbiology cultures of respiratory samples (sputum, cough swabs, throat swabs, ear swabs, bronchoalveolar lavage) and information on antibiotic resistance (in positive cultures)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Imaging results</measure>
    <time_frame>every 3 months up to 10 years</time_frame>
    <description>Radiological findings from sinus and lung imaging tests including x-rays, computed tomography and magnetic resonance imaging</description>
  </primary_outcome>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Primary Ciliary Dyskinesia</condition>
  <condition>Kartagener Syndrome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients of all ages diagnosed with PCD, followed in a PCD centre or other specialised
        clinic or registered in a national registry
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients diagnosed with primary ciliary dyskinesia

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Claudia E Kuehni, Prof</last_name>
    <phone>0041 316313507</phone>
    <email>claudia.kuehni@ispm.unibe.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Myrofora Goutaki, MD-PhD</last_name>
    <phone>0041 316315973</phone>
    <email>myrofora.goutaki@ispm.unibe.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Bern</name>
      <address>
        <city>Bern</city>
        <zip>3012</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia E Kuehni, Prof</last_name>
      <email>claudia.kuehni@ispm.unibe.ch</email>
    </contact>
    <contact_backup>
      <last_name>Myrofora Goutaki, MD-PhD</last_name>
      <email>myrofora.goutaki@ispm.unibe.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Goutaki M, Maurer E, Halbeisen FS, Amirav I, Barbato A, Behan L, Boon M, Casaulta C, Clement A, Crowley S, Haarman E, Hogg C, Karadag B, Koerner-Rettberg C, Leigh MW, Loebinger MR, Mazurek H, Morgan L, Nielsen KG, Omran H, Schwerk N, Scigliano S, Werner C, Yiallouros P, Zivkovic Z, Lucas JS, Kuehni CE; PCD Italian Consortium; Swiss PCD Group; French Reference Centre for Rare Lung Diseases; Genetic Disorders of Mucociliary Clearance Consortium. The international primary ciliary dyskinesia cohort (iPCD Cohort): methods and first results. Eur Respir J. 2017 Jan 4;49(1). pii: 1601181. doi: 10.1183/13993003.01181-2016. Print 2017 Jan.</citation>
    <PMID>28052956</PMID>
  </results_reference>
  <results_reference>
    <citation>Goutaki M, Halbeisen FS, Spycher BD, Maurer E, Belle F, Amirav I, Behan L, Boon M, Carr S, Casaulta C, Clement A, Crowley S, Dell S, Ferkol T, Haarman EG, Karadag B, Knowles M, Koerner-Rettberg C, Leigh MW, Loebinger MR, Mazurek H, Morgan L, Nielsen KG, Phillipsen M, Sagel SD, Santamaria F, Schwerk N, Yiallouros P, Lucas JS, Kuehni CE; PCD Israeli Consortium; Swiss PCD Group; French Reference Centre for Rare Lung Diseases. Growth and nutritional status, and their association with lung function: a study from the international Primary Ciliary Dyskinesia Cohort. Eur Respir J. 2017 Dec 21;50(6). pii: 1701659. doi: 10.1183/13993003.01659-2017. Print 2017 Dec.</citation>
    <PMID>29269581</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2018</study_first_submitted>
  <study_first_submitted_qc>April 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2018</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyskinesias</mesh_term>
    <mesh_term>Ciliary Motility Disorders</mesh_term>
    <mesh_term>Kartagener Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Researchers wanting to use the iPCD Cohort dataset can propose a research topic and draft a concept sheet describing the planned analyses and publication. All concept sheets have to be approved by all participating centres contributing data to the proposed analysis under question. After the participating centres agree to contribute their data and sign a publication agreement, the iPCD cohort managing centre (University of Bern) will prepare a partial dataset for the proposed analysis and will work closely with the lead researchers offering methodological input and support. In case additional data is collected to complete the partial dataset for a specific project, this will be added to the iPCD Cohort to enrich it after each project.
For further details, contact: pcd@ispm.unibe.ch</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

